Clinical trial NCT04766385: Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis
Official title: A Phase 3, Open-label, Single-arm Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hyperphosphatemia
Keywords: Tenapanor
Hyperphosphatemia
Peritoneal Dialysis
Lead sponsor: Kyowa Kirin Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-02-23
Enrollment: 54
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from baseline values between peritoneal dialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 for 8 weeks and those receiving placebo.


Eligibility criteria: Inclusion Criteria:

1. Has voluntarily provided written informed consent to participate in the study.
2. Aged ≥ 20 years (expressed in completed years) at the time of providing informed consent.
3. Stable chronic renal failure patients who have undergone peritoneal dialysis 3 times per week for at least 12 weeks until screening examination.
4. Dialysis conditions, should have been unchanged during the last 2 weeks before screening examination.
5. The prescribed drug and dosage regimen should have been unchanged during the last 2 weeks before screening examination.
6. Serum phosphorus levels should be in the range of ≥ 3.5 and ≤ 7.0 mg/dL at screening examination.
7. If on any vitamin D, calcimimetics regimen, bisphosphonate,calcitonin preparations, selective estrogen receptor modulators or teriparatide preparations then the prescribed drug and dosage regimen should have been unchanged for the last 4 weeks before screening examination.

Exclusion Criteria:

1. Subjects who received concomitant hemodialysis or hemodialysis filtration within 12 weeks before screening examination.
2. Having concurrent or a history of inflammatory bowel disease (IBD) or diarrhea-predominant irritable bowel syndrome
3. History of gastrectomy or enterectomy or having undergone gastrointestinal tract surgery within 3 months before screening examination.
4. Subjects in whom peritonitis, catheter-related infections, catheter dysfunction, etc. are confirmed within 4 weeks before screening examination., and the continuation of peritoneal dialysis is considered to be interfering with the implementation of peritoneal dialysis.
5. Subjects who used anti RANKL preparations within 6 weeks before screening examination.
6. Subjects who used anti-sclerostin antibody preparations within 12 weeks before screening examination.
7. Having concurrent severe heart disease or hepatic impairment.
8. Developed cerebrovascular disease or cardiovascular disease requiring hospitalization within 6 months before screening examination.
9. Subjects who have undergone parathyroid intervention within 24 weeks before screening examination., or subjects who are scheduled to undergo parathyroid intervention between the implementation of the pretest and the completion of the study.
10. Uncontrollable hypertension or diabetes.
11. Scheduled for living donor kidney transplant, change in the mode of dialysis, home hemodialysis, or change in the dialysis center (relocate to another hospital/clinic) during the study period.
12. Any diagnosis of and treatment of malignancy within 5 years before screening examination.

Primary outcomes:
measure: Changes in serum phosphorous levels from baseline values at 8 weeks after the start of administration.
timeFrame: Week 8
Secondary outcomes:
measure: Changes in serum phosphorous levels from baseline values at each time point.
timeFrame: Dose period, Week 2, 4, 6, 8, 10, 12, 14, 16.
measure: Achievement/failure of the target serum phosphorus level (serum phosphorus level: ≤ 6.0).
timeFrame: Dose period, Week 2, 4, 6, 8, 10, 12, 14, 16.
measure: Time when the target serum phosphorus level (serum phosphorus level: ≤ 6.0) was achieved.
timeFrame: Dose period, Week 2, 4, 6, 8, 10, 12, 14, 16.
measure: Achievement/failure of the target serum phosphorus level (serum phosphorus level: ≤ 5.5).
timeFrame: Dose period, Week 2, 4, 6, 8, 10, 12, 14, 16.
measure: Time when the target serum phosphorus level (serum phosphorus level: ≤ 5.5) was achieved.
timeFrame: Dose period, Week 2, 4, 6, 8, 10, 12, 14, 16.
measure: Concentrations of such as Ca × P product levels at each time point.
timeFrame: Dose period, Week 2, 4, 6, 8, 10, 12, 14, 16.
measure: Changes of such as Ca × P product levels from baseline values at each time point.
timeFrame: Dose period, Week 2, 4, 6, 8, 10, 12, 14, 16.
Other outcomes:
Locations:
city: Suita
country: Japan
facility: Inoue Hospital
state: Osaka
Study officials:
References: